| Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition … S Loi, N Sirtaine, F Piette, R Salgado, G Viale, F Van Eenoo, G Rouas, ... Journal of clinical oncology 31 (7), 860-867, 2013 | 1775 | 2013 |
| 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657, 2018 | 1243 | 2018 |
| De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 G Curigliano, HJ Burstein, E P. Winer, M Gnant, P Dubsky, S Loibl, ... Annals of Oncology 28 (8), 1700-1712, 2017 | 1240 | 2017 |
| 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ... Annals of Oncology, 2020 | 1071 | 2020 |
| 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3) F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ... Annals of Oncology 28 (1), 16-33, 2017 | 898 | 2017 |
| Adjuvant exemestane with ovarian suppression in premenopausal breast cancer O Pagani, MM Regan, BA Walley, GF Fleming, M Colleoni, I Láng, ... New England Journal of Medicine 371 (2), 107-118, 2014 | 889 | 2014 |
| Adjuvant ovarian suppression in premenopausal breast cancer PA Francis, MM Regan, GF Fleming, I Láng, E Ciruelos, M Bellet, ... New England Journal of Medicine 372 (5), 436-446, 2015 | 866 | 2015 |
| ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) F Cardoso, A Costa, L Norton, E Senkus, M Aapro, F André, CH Barrios, ... The Breast 23 (5), 489-502, 2014 | 851 | 2014 |
| Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers S Loi, D Drubay, S Adams, G Pruneri, PA Francis, M Lacroix-Triki, ... Journal of Clinical Oncology 37 (7), 559-569, 2019 | 693 | 2019 |
| Tailoring adjuvant endocrine therapy for premenopausal breast cancer PA Francis, O Pagani, GF Fleming, BA Walley, M Colleoni, I Láng, ... New England Journal of Medicine 379 (2), 122-137, 2018 | 644 | 2018 |
| Estimating the Benefits of Therapy for Early Stage Breast Cancer: The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019 H Burstein, G Curigliano, S Loibl, P Dubski, M Gnant, P Poortmans, ... Annals of Oncology 30 (10), 1541-1557, 2019 | 620 | 2019 |
| Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy HCF Moore, JM Unger, KA Phillips, F Boyle, E Hitre, D Porter, PA Francis, ... New England Journal of Medicine 372 (10), 923-932, 2015 | 613 | 2015 |
| Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 HJ Burstein, G Curigliano, B Thürlimann, WP Weber, P Poortmans, ... Annals of Oncology 32 (10), 1216-1235, 2021 | 534 | 2021 |
| 1st International consensus guidelines for advanced breast cancer (ABC 1) F Cardoso, A Costa, L Norton, D Cameron, T Cufer, L Fallowfield, ... The Breast 21 (3), 242-252, 2012 | 416 | 2012 |
| Strategies for the discovery and development of therapies for metastatic breast cancer BL Eckhardt, PA Francis, BS Parker, RL Anderson Nature Reviews Drug Discovery 11 (6), 479-497, 2012 | 380 | 2012 |
| Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer … R Gray, R Bradley, J Braybrooke, Z Liu, R Peto, L Davies, D Dodwell, ... The Lancet 393 (10179), 1440-1452, 2019 | 331 | 2019 |
| Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel JD Shapiro, MJ Millward, D Rischin, M Michael, V Walcher, PA Francis, ... Gynecologic oncology 63 (1), 89-93, 1996 | 295 | 1996 |
| Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. PA Francis, JR Rigas, MG Kris, KM Pisters, JP Orazem, KJ Woolley, ... Journal of clinical oncology 12 (6), 1232-1237, 1994 | 262 | 1994 |
| Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. P Francis, E Rowinsky, J Schneider, T Hakes, W Hoskins, M Markman Journal of clinical oncology 13 (12), 2961-2967, 1995 | 248 | 1995 |
| Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. P Francis, J Schneider, L Hann, C Balmaceda, R Barakat, M Phillips, ... Journal of clinical oncology 12 (11), 2301-2308, 1994 | 223 | 1994 |
Meredith M. Regan, ScDDana-Farber Cancer Institute, Harvard Medical School在 ds.dfci.harvard.edu 的电子邮件经过验证
